KOSDAQBiotech & Pharma082270

GemVax & KAEL

₩7,690▼ 3.39%2026-11-18 close
Market Cap
₩349.7B
Turnover
₩1.6B
Volume
200K
Shares out.
45.5M
PER
—
PBR
4.1×
EPS
-₩415
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Chip filters turned profit, but net losses persist

Semiconductor filter sales turned 2025 operating profit positive, but net losses attributable to controlling shareholders and an operating loss in Q3 2026 keep the financial burden in view.

  1. 1

    2025 revenue rose 30.1% to KRW 81.5 billion, and operating profit of KRW 3.79 billion turned the year positive.

  2. 2

    Net loss attributable to controlling shareholders was in the red for four consecutive years from 2022 to 2025, and the 2025 loss of KRW 11.3 billion narrowed from KRW 87.2 billion in 2024.

  3. 3

    Q3 2026 revenue reached KRW 23.4 billion, up 30.2% year on year, but the quarter swung to an operating loss of KRW 1.89 billion.

  4. 4

    The GV1001 pipeline has been designated a developmental-stage orphan drug for PSP, but no disclosed schedule yet points to commercialization timing.

  5. 5

    In August 2026 a third-party share allotment and a KRW 30 billion property acquisition decision followed each other, making the funding structure a key variable.

02

Business structure

GemVax & KAEL runs two businesses: contamination-control components used in semiconductor and display manufacturing, and peptide-based drug development. The company was founded in 1998, reorganized around its bio business, and listed on KOSDAQ in June 2005.

Its main products are contamination-control parts for semiconductor and display applications, and reports indicated that this business's sales grew at an average annual rate of 22% from 2010 to 2013. The company attributed the growth in 2025 mainly to a sharp expansion in semiconductor filter sales.

It says continuous R&D has raised its filter technology and emphasizes its distinctive competitiveness in the field. The drug business centers on GV1001, a peptide-based candidate pursued for neurodegenerative diseases including Alzheimer's disease and progressive supranuclear palsy (PSP).

GV1001 is a 16-amino-acid peptide containing the hTERT sequence, which the company says works through multiple mechanisms as several telomerase functions are expressed at once.

Korea's Ministry of Food and Drug Safety designated GV1001's PSP indication as a developmental-stage orphan drug, and a conditional approval application becomes possible if efficacy is confirmed in a domestic Phase 2 trial.

At year-end 2025, consolidated total assets were KRW 158.9 billion and total liabilities were KRW 101.6 billion, so funding allocation across the two businesses is tied to the financial burden.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩18B₩700M4.1%
2025Q4₩26.2B₩7.5B28.7%
2026Q1₩18.3B-₩800M−4.2%
2026Q2₩22.7B₩1B4.4%
2026Q3₩23.4B-₩1.9B−8.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩75.8B-₩3.9B-₩19.6B−5.2%−14.6%12.5%
2023₩72.2B-₩7.9B-₩27.2B−10.9%−25.2%25.1%
2024₩62.7B-₩38.3B-₩87.2B−61.2%−300.7%419.7%
2025₩81.5B₩3.8B-₩11.3B4.7%−19.8%177.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On the disclosed annual figures, revenue fell from KRW 75.8 billion in 2022 to KRW 72.2 billion in 2023, a decline of 4.7%, and then to KRW 62.7 billion in 2024, down 13.2%, making 2024 the smallest year of 2022 to 2025. Revenue rose 30.1% to KRW 81.5 billion in 2025, the largest year in the period.

Operating losses widened from KRW 3.95 billion in 2022 to KRW 7.87 billion in 2023 and KRW 38.3 billion in 2024, before 2025 posted operating profit of KRW 3.79 billion, a turnaround to profit.

The operating margin moved from -5.2% in 2022 and -10.9% in 2023 to -61.2% in 2024, when falling sales and a larger operating loss coincided, and reached 4.7% in 2025.

Net loss attributable to controlling shareholders widened from KRW 19.6 billion in 2022 and KRW 27.2 billion in 2023 to KRW 87.2 billion in 2024, then narrowed to KRW 11.3 billion in 2025. Net loss including non-controlling interests was also KRW 11.3 billion in 2025.

At the end of 2025, total equity was KRW 57.2 billion, all attributable to controlling shareholders, and the debt-to-equity ratio fell from 419.7% in 2024 to 177.6% in 2025. Operating cash flow was KRW -2.96 billion in 2022, KRW 3.57 billion in 2023, KRW -28.4 billion in 2024, and KRW 1.11 billion in 2025.

Quarterly, revenue of KRW 26.2 billion in Q4 2025 rose 45.5% from the prior quarter, and operating profit of KRW 752 million... the Q4 2025 operating profit of KRW 7.52 billion rose 923.0% from the prior quarter, and controlling-shareholder net profit of KRW 1.65 billion turned positive.

In Q1 2026 revenue fell 30.2% to KRW 18.3 billion and the operating result swung to a loss of KRW 765 million.

Q2 2026 returned to operating profit of KRW 997 million, and Q3 2026 revenue rose 3.1% from the prior quarter to KRW 23.4 billion, up 30.2% year on year, but the operating result swung to a loss of KRW 1.89 billion.

Revenue rose for two consecutive quarters from Q2 to Q3 2026, while operating results moved up and down each quarter. Net loss attributable to controlling shareholders was KRW 9.87 billion in Q2 2026 and KRW 8.62 billion in Q3 2026, the third straight quarter of losses since Q1 2026. The four quarters from Q4 2025 to Q3 2026 total a controlling-shareholder net loss of KRW 18.3 billion.

05

Industry analysis

The semiconductor filter business that lifted the company's results moves with the chip cycle. The company attributed 2025 growth to an unusual boom in the semiconductor industry, which drove a sharp rise in demand for filters as essential process consumables.

It said the semiconductor sector is in an unprecedented supercycle and expects its earnings momentum to continue. Filter demand can still shift with chip capital spending cycles, so the operating swings in 2026 despite higher quarterly revenue from Q2 onward call for watching both the cycle and the cost structure.

The drug side follows a different dynamic. Reports say global competition to develop PSP treatments has moved into late-stage clinical trials, so the differentiation of clinical data matters in a crowded field.

Compared with listed bio and pharma peers that have neurodegenerative pipelines, GemVax & KAEL's distinguishing feature is that its filter sales, not drug revenue, lead its results.

Because the bio sector is sensitive to clinical pace and partnering, how much cash the filter business can fund for drug development is a key yardstick for the company's position within the sector.

06

Outlook

The company expects its earnings momentum to continue, citing the semiconductor boom. Whether that view holds can be gauged by whether the sales growth that has run since Q2 2026 translates into operating profit, since Q3 2026 showed revenue rising without an improvement in the operating result.

On funding, the third-party share allotment moved sharply in August 2026.

A disclosure on August 13 said the new share count would expand to 1.38 million shares and that the third-party allottees would be entirely replaced, but on August 20 a correction reflecting actual payments reduced the issuance to 1.22 million shares.

The listing date for the new shares was pushed back from September 11 to September 16, 2026. On August 13, 2026, the company also decided to acquire land and buildings in Seocho-dong, Seoul, for KRW 30 billion.

Because that is large relative to total equity of KRW 57.2 billion, the payment method and financial impact should be checked against follow-up disclosures and the annual report. On the drug side, a conditional approval path for GV1001 in PSP depends on confirming efficacy in a domestic Phase 2 trial.

There have also been reports of FDA clearance for a Phase 2 study, but the distance to commercialization depends on clinical results and further fundraising.

A disclosure on November 11, 2026 said 5,000 treasury shares were disposed of to the CMO as a signing bonus, within a holding and disposal plan approved at the March 30, 2026 annual general meeting.

07

Valuation

PER
—
PBR
4.1×
ROE
-28.0%
EPS
-₩415
BPS
₩1,955
Dividend per share
₩0

Because the company has posted controlling-shareholder net losses across the last four quarters, its P/E cannot be calculated, so earnings-based multiples cannot directly compare the share price.

The price-to-book ratio sits in a range with a large premium over net asset value, which makes thin book equity relative to the share price the starting point of any comparison. The company pays no dividend, so its dividend yield is below the sector average.

Operating profit turned positive in 2025 while controlling-shareholder net losses remained, so the key question for the multiple is whether the earnings recovery extends past the operating line to net profit. It also matters whether profits from the filter business offset drug development costs.

The debt-to-equity ratio fell from 419.7% in 2024 to 177.6% in 2025, but liabilities still exceed equity, so the reading of the share price multiple changes with financial leverage.

Against its own past trading band the share price can be placed in context, and against sector averages the premium is different from that of drug-focused peers.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Steep recovery in semiconductor filter sales

Revenue rose 30.1% to KRW 81.5 billion in 2025, which the company attributed to higher semiconductor filter sales and lower selling and administrative costs. Revenue rose for two consecutive quarters from Q2 to Q3 2026, and Q3 revenue was up 30.2% year on year. If the company's read on the semiconductor boom holds, filter demand could keep supporting the revenue base.

Operating profit turned positive

The operating margin moved from -61.2% in 2024 to 4.7% in 2025, with operating profit of KRW 3.79 billion marking a turn to profit. Q4 2025 operating profit rose 923.0% from the prior quarter to KRW 7.52 billion.

Q2 2026 also posted operating profit of KRW 997 million, which shows some improvement in the operating earnings structure.

Orphan designation opens a drug pathway

The PSP indication for GV1001 was designated a developmental-stage orphan drug by Korea's Ministry of Food and Drug Safety. With that designation, a conditional approval application becomes possible if efficacy is confirmed in a domestic Phase 2 trial. Related reports said patient enrollment in the PSP Phase 2 study had reached 66 patients, or 88%.

09

Bear factors

Prolonged net losses for controlling shareholders

Net loss attributable to controlling shareholders was in the red for four consecutive years from 2022 to 2025. Losses have continued for three consecutive quarters from Q1 2026 through Q3 2026, and the four quarters from Q4 2025 to Q3 2026 total KRW 18.3 billion. The gap between operating profit and net profit has not been closed.

Financial burden and funding variables

Total liabilities were KRW 101.6 billion at the end of 2025, above total equity of KRW 57.2 billion. The debt-to-equity ratio fell to 177.6% in 2025 but remains high.

In August 2026 the third-party share allotment was enlarged to 1.38 million shares and then corrected to 1.22 million shares, and a KRW 30 billion property acquisition was also decided.

Cycle dependence and a weaker Q3 result

The company cited an unusual boom in the semiconductor industry as the main background to 2025 results. If that boom fades, filter demand could fall quickly. Q3 2026 revenue increased, but the quarter posted an operating loss of KRW 1.89 billion, a swing from the prior-year quarter. Revenue growth that did not translate into better earnings raises questions about the cost structure.

10

Risk factors

Litigation risk

On March 31, 2026 the company filed an appeal against the part of a March 27, 2026 damages judgment that went against it. The appeal asks for the adverse portion to be reversed and remanded to the Seoul High Court. The timing and outcome of the appeal are not yet set, and a result could bring provisions or cash outflows.

Funding and share dilution

The third-party share allotment changed its issuance size several times in August 2026, and the listing date of the new shares was pushed back to September 16. More new shares can dilute value per share. How the property payment and drug trial costs are funded leaves room for additional fundraising.

Drug development and concentration risk

Development of GV1001 for PSP depends on confirming efficacy in a domestic Phase 2 trial. Reports say global competition in PSP treatments has moved into late-stage trials.

Because revenue relies heavily on the semiconductor filter business, the company's ability to defend results would be limited if filter demand weakens.

11

What to watch next

  1. December 31, 2026 (fiscal year-end)

    The 2026 fiscal year closes. Operating results alternated between profit and loss across the first three quarters of 2026, so whether Q4 operating profit stays positive will determine the annual result.

  2. Around mid-March 2027

    Annual preliminary results for 2025 were announced on March 13, 2026. Whether the 2026 annual preliminary results follow a similar timetable is a point to check, since the fourth-quarter profit and the scale of the controlling-shareholder net loss become visible when the annual report confirms the figures.

  3. By March 31, 2027

    This is the deadline for the 2026 annual report. Alongside the 2026 annual results, debt-to-equity ratio and operating cash flow, it is the point to check how the KRW 30 billion property payment and the use of rights-offering proceeds are reported.

  4. Timing undetermined (appeal ruling)

    This is the point to watch for the outcome of the appeal filed on March 31, 2026. Once a ruling is issued, the damages amount and financial impact should become visible through disclosure.

12

Overall view

GemVax & KAEL turned operating profit positive in 2025 on revenue of KRW 81.5 billion and operating profit of KRW 3.79 billion, driven by higher semiconductor filter sales.

However, net loss attributable to controlling shareholders persisted for four consecutive years from 2022 to 2025, and in Q3 2026 revenue rose but the company returned to an operating loss of KRW 1.89 billion. The four quarters from Q4 2025 to Q3 2026 total a controlling-shareholder net loss of KRW 18.3 billion.

The debt-to-equity ratio fell to 177.6% in 2025, but liabilities still exceed equity. In August 2026 the rights-offering size changed and a KRW 30 billion property acquisition was decided.

On the drug side, GV1001 has an orphan designation for PSP and a conditional approval path, but commercialization timing depends on clinical results and funding.

Strengths are the recovery in filter sales and the turn to operating profit; weaknesses are the prolonged net losses, financial burden and reliance on the chip cycle. The next checkpoints are the Q4 operating result after fiscal year-end on December 31, 2026, and the 2026 annual report due by March 31, 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. etoday.co.kr
  2. medifonews.com
  3. edaily.co.kr
  4. medigatenews.com
  5. medicopharma.co.kr
  6. yakup.com
  7. genexine.com
  8. cdn.clinicaltrials.gov
  9. clinicaltrials.gov
  10. kr.investing.com
  11. edaily.co.kr
  12. biospectator.com
  13. digitaltoday.co.kr
  14. m.biospectator.com
  15. edaily.co.kr
  16. medicaltimes.com
  17. news.nate.com
  18. etoday.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis